Advertisement
GSK vs JNJ
Which Stock Would AI Choose? GlaxoSmithKline (GSK) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- GSK has demonstrated exceptional momentum in its Specialty Medicines unit, with double-digit growth in oncology, HIV, and immunology driving upgraded financial guidance in recent quarters, while its vaccines segment faces U.S. market headwinds.
- JNJ reported full-year 2025 revenue of $94.2 billion and has set a bold 2026 target of surpassing $100 billion, powered by accelerating oncology sales and its diversified MedTech (Medical Technology) portfolio, even as Stelara biosimilar competition erodes a key legacy franchise.
- GSK carries a significantly lower beta of approximately 0.30, indicating less sensitivity to broader market swings compared to JNJ, though both are widely regarded as defensive healthcare holdings.
- JNJ offers the advantage of business model diversification across pharmaceuticals and medical devices, while GSK is a more concentrated pure-play on innovative medicines and vaccines.
- Both companies maintain robust shareholder return programs — GSK has launched a £2 billion share buyback alongside a growing dividend, while JNJ generates nearly $20 billion in annual free cash flow to support its dividend and strategic acquisitions.
- Each stock faces distinct risk profiles: JNJ confronts ongoing talc litigation and the Stelara patent cliff, whereas GSK navigates a CEO transition and U.S. vaccine policy pressure.
Introduction
For investors evaluating large-cap healthcare exposure, GSK (GlaxoSmithKline plc) and JNJ (Johnson & Johnson) represent two compelling yet structurally different opportunities. GSK, headquartered in London, is a global biopharma company focused on specialty medicines, vaccines, and general medicines. JNJ, based in New Jersey, is a healthcare conglomerate spanning both Innovative Medicine and MedTech. This stock comparison examines how these two pharmaceutical giants stack up across recent performance, growth catalysts, risk factors, and market positioning — offering relevant context for long-term investors and active traders alike who seek informed relative performance analysis.
GSK Overview and Recent Performance
GSK has delivered one of its strongest operational stretches in years, with its Specialty Medicines division firmly established as the primary growth engine. In the third quarter of 2025, the company reported a 7% increase in turnover to £8.55 billion and raised its full-year guidance across all key metrics — targeting turnover growth of 6% to 7%, core operating profit growth of 9% to 11%, and core EPS (earnings per share) growth of 10% to 12%. Specialty Medicines, which now accounts for roughly 40% of total sales, posted a 16% revenue jump, driven by double-digit expansion in HIV, Respiratory Immunology & Inflammation, and Oncology.
Recent weeks have seen GSK shares trading near $51.76 on the NYSE, reflecting a gain of more than 47% over the trailing twelve months. The stock's ascent has been supported by a series of regulatory wins — including FDA (U.S. Food and Drug Administration) approvals for Blenrep in multiple myeloma, Penmenvy (a pentavalent meningococcal vaccine), and Blujepa for uncomplicated urinary tract infections — as well as the initiation of a £2 billion share buyback program, the company's first since 2013. That said, GSK faces ongoing headwinds in its U.S. vaccines business, where Shingrix and Arexvy sales have declined due to revised immunization recommendations and slower market uptake. The company is also navigating a CEO transition, with Chief Commercial Officer Luke Miels set to succeed Emma Walmsley, who steered the company through its post-Haleon separation transformation.
JNJ Overview and Recent Performance
JNJ (Johnson & Johnson) enters 2026 with considerable momentum, having closed full-year 2025 with reported sales of $94.2 billion — a 6.0% increase year-over-year — and fourth-quarter sales of $24.6 billion that beat consensus estimates. Chairman and CEO Joaquin Duato described 2025 as a "catapult year," citing record performance across the company's six priority areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. For 2026, management has guided to approximately $100.5 billion in revenue at the midpoint, which would mark the first time a pure-play healthcare company crosses that threshold.
The Innovative Medicine segment posted operational sales growth of 5.3% in 2025, with standout contributions from Darzalex (now a $14 billion annualized brand), Carvykti (which achieved blockbuster status by surpassing $1 billion in sales), Erleada, and the Rybrevant/Lazcluze combination. These oncology gains helped offset an approximate 1,040-basis-point headwind from Stelara, which began facing U.S. biosimilar competition in 2025. In MedTech, operational sales grew 5.4%, fueled by electrophysiology products, Abiomed cardiovascular devices, and contributions from the Shockwave Medical acquisition. JNJ shares have appreciated roughly 47% over the past twelve months, though the stock continues to carry litigation-related uncertainty stemming from talc lawsuits — including a $1.56 billion verdict currently under appeal — as well as execution risk around the planned spinoff of the DePuy Synthes orthopaedics business and the ongoing development of the OTTAVA robotic surgical system.
Trending AI Robots
In a market environment where speed and data-driven decision-making increasingly separate top performers from the crowd, Tickeron's Trending AI Robots page offers a curated window into the most promising algorithmic trading strategies available today. Tickeron hosts hundreds of AI-powered trading bots, each designed to trade thousands of different tickers using distinct trading styles, strategies, and timeframes — from short-duration swing trading to longer-term trend-following approaches. However, only those bots demonstrating the strongest alignment with current market conditions earn a place in the Trending AI Robots section. These featured bots exhibit a range of compelling performance statistics, with some achieving win rates above 70% and annualized returns that materially outpace broad market benchmarks, depending on the strategy and risk parameters employed. Whether you are monitoring GSK, JNJ, or other healthcare names, exploring the Trending AI Robots page can help you identify data-driven tools suited to your trading objectives.
Head-to-Head Comparison
Perhaps the most defining contrast between GSK and JNJ lies in business model architecture. JNJ operates as a diversified healthcare giant, balancing a $57-billion-plus Innovative Medicine business with a $30-billion-plus MedTech segment — a structure that provides natural revenue diversification and reduces dependence on any single drug franchise. GSK, by comparison, is a more focused pharmaceutical and vaccines play, with Specialty Medicines representing a growing share of its top line and a smaller general medicines portfolio filling out the remainder. This concentration has worked in GSK's favor recently as its oncology and HIV franchises have accelerated, but it also means the company has fewer offsets when a segment — such as U.S. vaccines — underperforms.
On the growth front, GSK's Specialty Medicines unit is expanding at a mid-teens percentage rate, outpacing JNJ's blended operational sales growth of 5% to 6%. However, JNJ's absolute scale is formidable: with nearly $95 billion in 2025 revenue, the company generates roughly double GSK's annual turnover. Both companies must navigate significant patent exposure — Stelara for JNJ and the dolutegravir HIV franchise for GSK (with expiry expected in the 2028–2029 window) — but each has built robust pipelines to bridge these gaps. In terms of risk, JNJ's talc litigation overhang and Stelara erosion are more immediate and quantifiable, while GSK's primary uncertainties revolve around CEO transition execution and the evolving U.S. vaccine policy landscape. From a market sentiment standpoint, both stocks have enjoyed strong twelve-month runs, though GSK's lower beta and higher dividend yield may appeal more to income-oriented investors, while JNJ's scale and MedTech exposure offer a different risk-reward profile.
Tickeron AI Verdict
Based on observable trend consistency, relative momentum, and the balance of near-term catalysts against identifiable risks, Tickeron's AI-driven analytical framework would likely tilt in favor of GSK in the current market environment. The company's Specialty Medicines division continues to demonstrate accelerating revenue growth, earnings estimates have been revised upward consistently across recent quarters, and the stock's lower beta suggests a smoother trend profile that algorithmic models tend to favor. That said, this probabilistic assessment comes with important caveats — JNJ's unparalleled scale, diversified cash flows, and rapidly expanding oncology portfolio make it an exceptionally resilient compounder, and any favorable resolution of its litigation exposure could shift the relative positioning materially. As always, the AI verdict reflects a snapshot of current conditions and should be interpreted as one analytical input among many in a comprehensive investment research process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Buy and JNJ is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 1 FA rating(s) are green whileJNJ’s FA Score has 4 green FA rating(s).
- GSK’s FA Score: 1 green, 4 red.
- JNJ’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 5 TA indicator(s) are bullish while JNJ’s TA Score has 5 bullish TA indicator(s).
- GSK’s TA Score: 5 bullish, 4 bearish.
- JNJ’s TA Score: 5 bullish, 4 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а -3.85% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +3.72% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.06%. For the same industry, the average monthly price growth was +1.64%, and the average quarterly price growth was +4.51%.
Reported Earning Dates
GSK is expected to report earnings on Jul 28, 2026.
JNJ is expected to report earnings on Oct 20, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.06% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GSK | JNJ | GSK / JNJ | |
| Capitalization | 102B | 635B | 16% |
| EBITDA | 10.1B | 33.7B | 30% |
| Gain YTD | 5.251 | 26.672 | 20% |
| P/E Ratio | 13.51 | 30.56 | 44% |
| Revenue | 32.8B | 96.4B | 34% |
| Total Cash | 3.44B | 22.1B | 16% |
| Total Debt | 19.1B | 55B | 35% |
GSK | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 39 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 43 | 5 | |
SMR RATING 1..100 | 27 | 36 | |
PRICE GROWTH RATING 1..100 | 50 | 11 | |
P/E GROWTH RATING 1..100 | 77 | 13 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (79). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
JNJ's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (43). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
GSK's SMR Rating (27) in the Pharmaceuticals Major industry is in the same range as JNJ (36). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (11) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (50). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
JNJ's P/E Growth Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (77). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
| GSK | JNJ | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 31% |
| Stochastic ODDS (%) | 2 days ago 63% | 2 days ago 46% |
| Momentum ODDS (%) | 2 days ago 47% | 2 days ago 48% |
| MACD ODDS (%) | 2 days ago 49% | 2 days ago 33% |
| TrendWeek ODDS (%) | 2 days ago 53% | 2 days ago 44% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 48% |
| Advances ODDS (%) | 9 days ago 62% | 2 days ago 44% |
| Declines ODDS (%) | 2 days ago 54% | 10 days ago 42% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 42% |
| Aroon ODDS (%) | 2 days ago 51% | 2 days ago 42% |
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.